Stock listing
Stuttgart:ZVA Cellectis S.A. Aktie
German listing (Stuttgart) of Cellectis S.A. · home listing Euronext:ALCLS
Follow Cellectis S.A. into a list and get an email when it puts out news.
Home listing price · EURONEXT:ALCLS
€0.91 EUR -0.08 (-8.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, EURONEXT:ALCLS
- Day range
- €0.903 – €0.999 EURNov 20, 2026
- Volume
- 285,262 sharesNov 20, 2026
- Market cap
- €66.19M EURAt the close on Nov 20, 2026 · price × 72.73M shares outstanding
- 52-week range
- €0.895 – €4.75 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €617,767 EURMedian day 272,243 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:ALCLS · Home | €0.91 EUR | -0.079 (-8.0%) | 285,262 | €0.999 | €0.999 | €0.903 | €0.989 | Close on Nov 20, 2026 |
| NASDAQ:CLLS | $0.921 USD | -0.063 (-6.4%) | 52,626 | $0.990 | $0.996 | $0.903 | $0.984 | Close on Nov 20, 2026 |
| OTC:CMVLF | $1.014 USD | +0.022 (+2.2%) | 4,000 | $1.014 | $1.014 | $1.014 | $0.992 | Close on Nov 20, 2026 |
| Frankfurt:ZVAA | €0.855 EUR | -0.040 (-4.5%) | — | €0.855 | €0.855 | €0.855 | €0.895 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:ALCLS · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.91 | -0.079 | -8.0% | €0.999 | €0.999 | €0.903 | 285,262 | |
| €0.989 | -0.024 | -2.4% | €1.058 | €1.058 | €0.977 | 159,201 | |
| €1.013 | +0.013 | +1.3% | €1.001 | €1.069 | €0.955 | 489,656 | |
| €1.00 | -0.056 | -5.3% | €1.05 | €1.10 | €1.00 | 320,365 | |
| €1.056 | -0.224 | -17.5% | €1.07 | €1.17 | €1.01 | 1,980,513 | |
| €1.28 | -0.071 | -5.3% | €1.30 | €1.376 | €1.20 | 1,268,732 | |
| €1.351 | +0.302 | +28.8% | €1.088 | €1.351 | €1.047 | 1,607,758 | |
| €1.049 | -0.002 | -0.2% | €1.005 | €1.095 | €1.005 | 340,407 | |
| €1.051 | +0.046 | +4.6% | €1.029 | €1.057 | €1.00 | 274,413 | |
| €1.005 | -0.043 | -4.1% | €1.002 | €1.047 | €0.981 | 145,483 | |
| €1.048 | +0.02 | +1.9% | €1.072 | €1.089 | €1.011 | 337,007 | |
| €1.028 | -0.013 | -1.2% | €1.04 | €1.076 | €1.013 | 230,372 | |
| €1.041 | +0.061 | +6.2% | €0.999 | €1.066 | €0.952 | 351,521 | |
| €0.98 | -0.058 | -5.6% | €0.954 | €1.009 | €0.947 | 239,611 | |
| €1.038 | -0.064 | -5.8% | €1.14 | €1.14 | €1.026 | 337,053 | |
| €1.102 | -0.026 | -2.3% | €1.14 | €1.167 | €1.088 | 501,285 | |
| €1.128 | +0.153 | +15.8% | €0.984 | €1.19 | €0.98 | 1,147,028 | |
| €0.975 | +0.036 | +3.8% | €0.973 | €0.979 | €0.895 | 522,092 | |
| €0.939 | 0.00 | 0.0% | €0.96 | €0.964 | €0.936 | 105,247 | |
| €0.939 | -0.008 | -0.8% | €0.988 | €0.988 | €0.926 | 155,909 | |
| €0.947 | -0.048 | -4.9% | €0.976 | €0.976 | €0.932 | 291,553 | |
| €0.995 | +0.045 | +4.8% | €0.915 | €1.048 | €0.915 | 466,148 | |
| €0.95 | -0.002 | -0.2% | €0.942 | €0.958 | €0.908 | 626,558 | |
| €0.952 | -0.081 | -7.9% | €1.014 | €1.014 | €0.942 | 553,162 | |
| €1.033 | -0.01 | -1.0% | €1.069 | €1.083 | €1.021 | 108,181 | |
| €1.043 | -0.029 | -2.7% | €1.105 | €1.105 | €1.038 | 226,054 | |
| €1.072 | +0.022 | +2.1% | €1.056 | €1.11 | €1.05 | 303,598 | |
| €1.05 | -0.089 | -7.8% | €1.13 | €1.13 | €1.04 | 588,187 | |
| €1.139 | +0.011 | +1.0% | €1.127 | €1.185 | €1.127 | 152,505 | |
| €1.128 | +0.002 | +0.2% | €1.12 | €1.159 | €1.112 | 88,681 | |
| €1.126 | -0.102 | -8.3% | €1.19 | €1.192 | €1.111 | 352,532 | |
| €1.228 | -0.02 | -1.6% | €1.23 | €1.25 | €1.182 | 184,226 | |
| €1.248 | -0.001 | -0.1% | €1.255 | €1.311 | €1.201 | 184,937 | |
| €1.249 | -0.005 | -0.4% | €1.255 | €1.285 | €1.225 | 175,484 | |
| €1.254 | -0.036 | -2.8% | €1.277 | €1.282 | €1.23 | 271,580 | |
| €1.29 | -0.045 | -3.4% | €1.30 | €1.322 | €1.272 | 89,299 | |
| €1.335 | +0.064 | +5.0% | €1.29 | €1.365 | €1.255 | 652,521 | |
| €1.271 | -0.008 | -0.6% | €1.257 | €1.309 | €1.228 | 430,994 | |
| €1.279 | +0.031 | +2.5% | €1.268 | €1.30 | €1.258 | 253,875 | |
| €1.248 | +0.033 | +2.7% | €1.238 | €1.257 | €1.208 | 176,646 | |
| €1.215 | -0.025 | -2.0% | €1.227 | €1.248 | €1.192 | 258,051 | |
| €1.24 | -0.151 | -10.9% | €1.36 | €1.392 | €1.224 | 760,288 | |
| €1.391 | +0.067 | +5.1% | €1.334 | €1.447 | €1.301 | 634,839 | |
| €1.324 | +0.013 | +1.0% | €1.339 | €1.374 | €1.275 | 506,539 | |
| €1.311 | +0.089 | +7.3% | €1.274 | €1.38 | €1.188 | 1,069,350 | |
| €1.222 | +0.071 | +6.2% | €1.101 | €1.305 | €1.093 | 1,834,240 | |
| €1.151 | -0.199 | -14.7% | €1.298 | €1.34 | €1.151 | 2,067,466 | |
| €1.35 | -0.155 | -10.3% | €1.548 | €1.68 | €1.26 | 2,664,311 | |
| €1.505 | -1.129 | -42.9% | €1.762 | €1.79 | €1.444 | 1,356,429 | |
| €2.634 | -0.104 | -3.8% | €2.72 | €2.746 | €2.62 | 129,898 | |
| €2.738 | -0.002 | -0.1% | €2.736 | €2.844 | €2.722 | 64,220 | |
| €2.74 | -0.08 | -2.8% | €2.764 | €2.784 | €2.69 | 141,892 | |
| €2.82 | -0.09 | -3.1% | €2.91 | €2.91 | €2.796 | 152,104 | |
| €2.91 | +0.106 | +3.8% | €2.868 | €2.956 | €2.812 | 88,762 | |
| €2.804 | -0.144 | -4.9% | €2.94 | €2.994 | €2.804 | 82,746 | |
| €2.948 | +0.106 | +3.7% | €2.822 | €2.994 | €2.822 | 119,861 | |
| €2.842 | -0.008 | -0.3% | €2.92 | €3.028 | €2.802 | 134,932 | |
| €2.85 | -0.084 | -2.9% | €2.89 | €2.918 | €2.75 | 177,049 | |
| €2.934 | -0.108 | -3.6% | €3.10 | €3.11 | €2.902 | 109,092 | |
| €3.042 | -0.058 | -1.9% | €3.08 | €3.15 | €2.98 | 177,292 | |
| €3.10 | +0.07 | +2.3% | €3.00 | €3.16 | €3.00 | 272,906 | |
| €3.03 | +0.092 | +3.1% | €2.938 | €3.086 | €2.91 | 256,077 | |
| €2.938 | +0.182 | +6.6% | €2.70 | €2.938 | €2.70 | 88,600 | |
| €2.756 | -0.114 | -4.0% | €2.858 | €2.884 | €2.734 | 83,162 | |
| €2.87 | -0.09 | -3.0% | €2.90 | €2.97 | €2.858 | 82,146 | |
| €2.96 | +0.216 | +7.9% | €2.768 | €2.976 | €2.768 | 356,645 |
Splits
1 split · EURONEXT:ALCLS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split |
- Ticker
- Stuttgart:ZVA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Nov 13, 2026
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
Latest earnings call · May 11, 2026
Cellectis (Euronext:ALCLS) Q1 2026 Earnings Call
Replay and transcript
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 35 slides
Latest news
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
Nov 13, 2026
Closed €1.06 (-17.5%) on Nov 13, 2026
Cellectis to Report Third Quarter Financial Results on November 12, 2026
Nov 9, 2026
Closed €1.05 (+4.6%) on Nov 9, 2026
Monthly information on share capital and company voting rights
Nov 4, 2026
Closed €1.03 (-1.2%) on Nov 4, 2026
Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with.HEAL-101 at ESGCT 2026
Oct 27, 2026
Closed €0.975 (+3.8%) on Oct 27, 2026
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
Sep 14, 2026
Closed €1.51 (-42.9%) on Sep 14, 2026
Cellectis annonce sa transformation stratégique en société d'édition du génome in vivo
Sep 13, 2026
Closed €1.51 (-42.9%) on Sep 14, 2026
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
Sep 10, 2026
Closed €2.63 (-3.8%) on Sep 11, 2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Sep 2, 2026
Closed €2.95 (+3.7%) on Sep 3, 2026
Cellectis Announces Participation in Upcoming Investor Conferences
Sep 1, 2026
Closed €2.84 (-0.3%) on Sep 2, 2026
Cellectis annonce sa participation à plusieurs conférences investisseurs
Aug 31, 2026
Closed €2.85 (-2.9%) on Sep 1, 2026
Cellectis S.A. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 47 in all · newest Nov 13, 2026 · oldest 2025
- Calls
- 12 calls with a replay · 12 with a transcript · latest May 11, 2026
- Decks
- 35 decks · latest November 2026
Where Cellectis S.A. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:ALCLS · Home listing | Euronext | France | EUR |
| NASDAQ:CLLS | NASDAQ | United States | USD |
| gettex:ZVA | gettex | Germany | EUR |
| LS Exchange:A0MKPR | LS Exchange | Germany | EUR |
| LSIN:0WA2 | LSIN | United Kingdom | EUR |
| Lang & Schwarz:A0MKPR | Lang & Schwarz | Germany | EUR |
| Tradegate:ZVA | Tradegate | Germany | EUR |
| BOATS:CLLS | BOATS | United States | USD |
| gettex:ZVAA | gettex | Germany | EUR |
| Lang & Schwarz:A14QZE | Lang & Schwarz | Germany | EUR |
| Munich:ZVA | Munich | Germany | EUR |
| Hamburg:ZVA | Hamburg | Germany | EUR |
| OTC:CMVLF | OTC | United States | USD |
| Tradegate:ZVAA | Tradegate | Germany | EUR |
| Aquis:ALCLSP | Aquis | United Kingdom | EUR |
| Aquis:ALCLSP | Aquis | United Kingdom | EUR |
| Dusseldorf:ZVA | Dusseldorf | Germany | EUR |
| Dusseldorf:ZVAA | Dusseldorf | Germany | EUR |
| Frankfurt:ZVA | Frankfurt | Germany | EUR |
| Frankfurt:ZVAA | Frankfurt | Germany | EUR |
| LS Exchange:A14QZE | LS Exchange | Germany | EUR |
| Stuttgart:ZVA · This page | Stuttgart | Germany | EUR |
| Stuttgart:ZVAA | Stuttgart | Germany | EUR |
| Turquoise:ALCLSP | Turquoise | United Kingdom | EUR |
Valuation
EV/sales −0.2× against a median of 74.5×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −€8.78M EUR
- P/E
- Loss
- EV/sales
- −0.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.8×
- Gross margin
- 74.7%
- Operating margin
- −107.9%
- Net margin
- −115.4%
- Debt to equity
- 2.1×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cellectis S.A. · EURONEXT:ALCLS | US$72.64M | −US$9.64M | n/a | −0.2× | n/a | 1.8× | −115.4% | 2.1× | n/a |
| Recce Pharmaceuticals Ltd. · ASX:RCE | US$75.90M | US$81.02M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Black Diamond Therapeutics, Inc. · NASDAQ:BDTX | US$75.28M | −US$10.71M | n/a | n/a | n/a | 0.8× | n/a | 0.2× | 1.76 |
| Great Novel Therapeutics Biotech & Medicals Corp. · TPEX:7427 | US$73.93M | US$52.73M | n/a | 1,442× | n/a | 3.2× | n/a | 0.0× | n/a |
| Pentixapharm Holding AG · XETR:PTP | US$73.87M | US$69.92M | n/a | 1,158× | n/a | 2.4× | n/a | 0.0× | n/a |
| Dimerix Limited · ASX:DXB | US$73.52M | US$62.98M | n/a | 21.9× | n/a | n/a | −685.3% | n/a | n/a |
| Faron Pharmaceuticals Oy · LSE:FARN | US$72.99M | US$57.36M | n/a | n/a | n/a | 5.7× | n/a | 1.5× | n/a |
| Kanaph Therapeutics Inc. · KRX:0082N0 | US$72.81M | US$39.07M | n/a | 9.3× | n/a | 2.1× | −729.8% | 0.0× | n/a |
| Eastwood Bio-Medical Canada Inc · TSXV:EBM | US$72.06M | US$72.05M | n/a | 127× | n/a | n/a | −28.5% | n/a | 0.56 |
| SynAct Pharma AB · OMXSTO:SYNACT | US$71.20M | US$71.51M | n/a | n/a | n/a | 5.1× | n/a | 0.3× | n/a |
| Bioton S.A. · GPW:BIO | US$70.63M | US$86.88M | n/a | 1.4× | 6.5× | 0.5× | −3.3% | 0.1× | n/a |
| Median of the others | US$73.25M | US$66.45M | 74.5× | 6.5× | 2.4× | −356.9% | 0.1× | 1.16 |
Forecasts
Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.50 EUR · Analysts' mean
- EPS, year to Dec 2026
- -0.74 · 1 analyst
- Revenue, year to Dec 2026
- 56.24M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| André Choulika | Chief Executive Officer & Director |
| Patricia Sosa Navarro | Chief of Staff to the CEO |
| Arthur Stril | Chief Financial Officer & Chief Business Officer |
| Marie-Bleuenn Terrier | General Counsel |
| David Sourdive | Executive Vice President CMC & Manufacturing and Director |
| Kyung Nam-Wortman | Executive Vice President, Chief Human Resources Officer |
| Steve Doares | Senior Vice President, US Manufacturing and Site Head |
| Adrian Kilcoyne | Chief Medical Officer |
| Philippe Duchateau | Chief Scientific Officer |
| Stephan Reynier | Chief Regulatory and Pharmaceutical Compliance Officer |
Board
| Director | Role |
|---|---|
| Jean-Pierre Garnier | Chairman of the Board of Directors - Director |
| André Choulika | Chief Executive Officer & Director |
| David Sourdive | Executive Vice President CMC & Manufacturing and Director |
Events
- Next results
- Mar 18, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Cellectis (Euronext:ALCLS) Q1 2026 Earnings Call | Mon, May 11, 2026 | Replay |
| Cellectis (Euronext:ALCLS) Q4 2025 Earnings Call | Fri, Mar 20, 2026 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q2 2025 Earnings Call | Tue, Aug 05, 2025 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q4 2024 Earnings Call | Fri, Mar 14, 2025 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q1 2024 Earnings Call | Wed, May 29, 2024 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q3 2023 Earnings Call | Tue, Nov 07, 2023 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q2 2023 Earnings Call | Fri, Aug 04, 2023 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q1 2023 Earnings Call | Fri, May 05, 2023 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q4 2022 Earnings Call | Thu, Mar 09, 2023 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q3 2022 Earnings Call | Fri, Nov 04, 2022 · 8:00 AM ET | Replay |
All 12 calls
| Call | When | Status |
|---|---|---|
| Cellectis (Euronext:ALCLS) Q2 2022 Earnings Call | Fri, Aug 05, 2022 · 8:00 AM ET | Replay |
| Cellectis (Euronext:ALCLS) Q4 2021 Earnings Call | Fri, Mar 04, 2022 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 12, 2026 · After close | −17.5% |
| Q2 2026 | Aug 6, 2026 · After close | −0.5% |
| Q1 2026 | May 11, 2026 · After close | +1.7% |
| Q4 2025 | Mar 19, 2026 · After close | −1.4% |
| Q3 2025 | Nov 7, 2025 · After close | +12.2% |
| Q2 2025 | Aug 4, 2025 · After close | −15.1% |
| Q1 2025 | May 12, 2025 · After close | −1.3% |
| Q4 2024 | Mar 13, 2025 · After close | −1.9% |
| Q3 2024 | Nov 4, 2024 · After close | −1.5% |
| Q2 2024 | Aug 6, 2024 · After close | +3.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 29, 2024 · After close | −0.6% |
| Q4 2023 | Mar 13, 2024 · After close | −1.2% |
| Q3 2023 | Nov 6, 2023 · After close | −1.8% |
| Q2 2023 | Aug 3, 2023 · After close | −1.6% |
| Q1 2023 | May 4, 2023 · After close | +1.7% |
| Q4 2022 | Mar 8, 2023 · After close | −3.1% |
| Q3 2022 | Nov 3, 2022 · After close | −5.7% |
| Q2 2022 | Aug 4, 2022 · After close | +9.4% |
| Q1 2022 | May 12, 2022 · After close | +1.6% |
| Q4 2021 | Mar 3, 2022 · After close | −3.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 35 slides | November 2026 |
| Corporate Update (September 2026) | Corporate update | 40 slides | Sep 14, 2026 |
| Corporate Update (September 2026) | Corporate update | 40 slides | Sep 14, 2026 |
| Corporate Update (September 2026) | Corporate update | 41 slides | Sep 14, 2026 |
| EHA 2026 | Conference | 23 slides | Jun 15, 2026 |
| Investor Day (June 2026) | Investor day | 65 slides | June 2026 |
| Q1 2026 Earnings Presentation | Earnings | 31 slides | May 11, 2026 |
| Investor Presentation (May 2026) | Investor deck | 31 slides | May 2026 |
| Investor Presentation (November 2025) | Investor deck | 32 slides | November 2025 |
| Investor Day (October 2025) | Investor day | 65 slides | Oct 17, 2025 |
All 35 decks
IPO
Priced at US$41.50 an ADS on Mar 24, 2015.
- Price
- US$41.50 an ADS
- ADSs offered
- 5,500,000 American depositary shares
- Offering size
- US$228.3 million
- Underwriters' option
- Up to 825,000 more ADSs
- Underwriters
- BofA Merrill Lynch, Jefferies, Piper Jaffray, Oppenheimer & Co., Trout Capital · In the order on the cover
- ADSs delivered
- On or about Mar 30, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 19, 2014 |
| Filed publicly | Feb 20, 2015 |
| Amended 4 times | Newest Mar 24, 2015 |
| Shares registered with an exchange | Mar 23, 2015 |
| Declared effective by the SEC | Mar 24, 2015 |
| Final prospectus, with the price | Mar 26, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B1 · Prospectus | Mar 26, 2015 |
| EFFECT · Notice that a registration is effective | Mar 24, 2015 |
| F-1MEF · Registration of more shares for the same offering | Mar 24, 2015 |
| CERTNAS · Nasdaq's certificate of listing | Mar 24, 2015 |
| FWP · Free writing prospectus | Mar 24, 2015 |
| F-1/A · Registration statement, amended | Mar 24, 2015 |
| CORRESP · Letter to the SEC | Mar 23, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 23, 2015 |
| F-1/A · Registration statement, amended | Mar 18, 2015 |
| F-1/A · Registration statement, amended | Mar 12, 2015 |
All 19 filings
| Filing | Filed |
|---|---|
| F-1/A · Registration statement, amended | Mar 10, 2015 |
| F-1 · Registration statement | Feb 20, 2015 |
| DRS/A · Draft registration statement, amended | Feb 12, 2015 |
| DRSLTR · Letter to the SEC with a draft | Feb 12, 2015 |
| UPLOAD · Letter from the SEC | Feb 9, 2015 |
| DRSLTR · Letter to the SEC with a draft | Jan 27, 2015 |
| DRS/A · Draft registration statement, amended | Jan 27, 2015 |
| UPLOAD · Letter from the SEC | Jan 16, 2015 |
| DRS · Draft registration statement | Dec 19, 2014 |
Open IPO · From the cover of the final prospectus (424B1) filed Mar 26, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.9M | 41.5M | 755.0K | 19.2M | 30.3M | 51.1M | 15.2M | 12.7M | 25.2M | 44.8M |
| Cost of revenue | 0 | 0 | 737.0K | 1.77M | 1.84M | 1.95M | 11.4M | 2.74M | 2.62M | 1.69M |
| Gross profit | 55.0M | 41.5M | 18.0K | 17.4M | 37.7M | 37.7M | 3.80M | 9.99M | 22.6M | 40.9M |
| Research and development | 93.5M | 90.5M | 87.6M | 97.5M | 117.8M | 77.0M | 92.0M | 76.6M | 79.2M | 78.5M |
| Selling, general and administrative | 19.8M | 19.1M | 16.8M | 17.5M | 22.9M | 22.5M | 43.0M | 47.2M | 44.8M | 43.4M |
| Operating income | -33.1M | -59.6M | -97.3M | -89.7M | -103.5M | -42.3M | -123.6M | -105.1M | -92.7M | -67.3M |
| Depreciation and amortization | 20.1M | 19.8M | 18.5M | 18.4M | 14.2M | 7.83M | 6.88M | 2.38M | 3.37M | 2.21M |
| EBITDA | -13.0M | -39.7M | -78.8M | -71.2M | -89.3M | -34.5M | -116.7M | -102.7M | -89.3M | -65.1M |
| Interest expense | 51.1M | 21.6M | 40.6M | 371.0K | 368.0K | 73.0K | 3.00K | 39.0K | 0 | 7.10M |
| Income before tax | -68.0M | -36.8M | -116.5M | -98.6M | -96.7M | -53.6M | -115.2M | -88.3M | -103.7M | -67.3M |
| Income tax | -423.0K | 0 | 371.0K | 87.0K | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -67.6M | -36.8M | -101.1M | -106.1M | -114.2M | -81.1M | -102.1M | -78.7M | -99.4M | -67.3M |
| Earnings per share, basic | -0.67 | -0.41 | -1.77 | -2.33 | -2.55 | -1.91 | -2.41 | -1.93 | -2.78 | -1.91 |
| Earnings per share, diluted | -0.67 | -0.41 | -1.77 | -2.33 | -2.55 | -1.91 | -2.41 | -1.93 | -2.78 | -1.91 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 61.5M | 143.3M | 136.7M | 93.2M | 185.6M | 241.1M | 340.5M | 451.5M | 256.4M | 254.6M |
| Short-term investments | 147.1M | 117.1M | 67.1M | 7.91M | 499.0K | 27.1M | 20.4M | 388.0K | 40.6M | 36.5M |
| Receivables | 14.4M | 6.71M | 569.0K | 772.0K | 20.4M | 5.17M | 2.96M | 2.97M | 2.75M | 3.63M |
| Inventory | 89.7M | 0 | 0 | 1.60M | 2.90M | 275.0K | 250.0K | 118.0K | ||
| Current assets | 236.2M | 287.1M | 233.0M | 122.0M | 225.4M | 315.4M | 391.5M | 487.6M | 323.2M | 312.5M |
| Property, plant and equipment | 38.8M | 45.9M | 54.7M | 63.6M | 78.8M | 71.7M | 23.7M | 8.73M | 7.23M | 16.9M |
| Goodwill | -1.00K | 1.00K | -1.00K | 0 | ||||||
| Total assets | 324.7M | 383.5M | 334.3M | 261.2M | 382.1M | 469.5M | 467.5M | 500.8M | 332.9M | 331.4M |
| Accounts payable | 17.3M | 18.7M | 19.1M | 21.5M | 23.8M | 24.6M | 29.3M | 15.9M | 9.46M | 9.72M |
| Current liabilities | 145.8M | 166.3M | 155.1M | 48.1M | 49.3M | 52.0M | 62.6M | 46.9M | 45.5M | 56.2M |
| Long-term debt | 51.2M | 44.0M | 28.4M | 20.5M | 20.0M | 28.8M | 46.5M | 1.02M | 13.0K | 29.4K |
| Total debt | 90.7M | 91.5M | 85.1M | 82.8M | 102.2M | 111.3M | 47.6M | 1.35M | 34.0K | 1.76M |
| Total liabilities | 248.8M | 252.5M | 249.6M | 135.3M | 145.6M | 160.6M | 112.0M | 50.6M | 47.0M | 56.6M |
| Shareholders' equity | 75.9M | 131.0M | 84.7M | 118.0M | 221.3M | 283.8M | 315.1M | 409.3M | 264.9M | 272.8M |
| Shares outstanding | 100.3M | 100.1M | 71.8M | 45.7M | 45.5M | 42.8M | 42.5M | 42.4M | 36.0M | 35.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -39.4M | 23.0M | -24.7M | -87.4M | -104.6M | -80.3M | -69.1M | -68.1M | -52.3M | -32.7M |
| Capital spending | -2.36M | -2.58M | -1.07M | -2.43M | -18.5M | -44.1M | -12.9M | -4.71M | -2.38M | -13.7M |
| Free cash flow | -41.8M | 20.4M | -25.8M | -89.9M | -123.1M | -124.3M | -82.1M | -72.9M | -54.7M | -46.4M |
| Cash from investing | -29.5M | -102.8M | -15.5M | -2.76M | 7.28M | -54.3M | -35.9M | 35.6M | 1.78M | -53.1M |
| Cash from financing | -16.8M | 89.1M | 82.9M | 1.15M | 47.5M | 27.3M | -3.86M | 236.5M | 41.3M | 485.0K |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Share buybacks | 44.0K | 82.8M | 67.9M | -569.0K | 15.5M | 9.55M | -469.0K | 186.7M | 3.05M | -137.0K |
| Change in cash | -85.6M | 9.29M | 42.6M | -89.1M | -49.8M | -107.3M | -108.9M | 204.0M | -9.28M | -85.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update | Nov 13, 2026 | Results | Euronext |
| 6-K · Report of a foreign issuer | Nov 13, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 9, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 9, 2026 | Big-stake notice | SEC |
| Cellectis to Report Third Quarter Financial Results on November 12, 2026 | Nov 9, 2026 | Results | Euronext |
| Monthly information on share capital and company voting rights | Nov 4, 2026 | Other filings | Euronext |
| 6-K · Report of a foreign issuer | Oct 28, 2026 | Current report | SEC |
| Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026 | Oct 27, 2026 | Other filings | Euronext |
| 6-K · Report of a foreign issuer | Sep 14, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 547 filings. Open Filings
Cap table
Built by 6ix from Cellectis S.A.’s releases
- Common shares
- 72,732,781
- Fully diluted
- 72,732,781
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 72,732,781 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 72,732,781 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Adrian Kilcoyne | Chief Medical Officer · Since at least May 12, 2026 |
| André Choulika | Chief Executive Officer & Director · Since at least Sep 14, 2026 |
| Arthur Stril | Chief Financial Officer & Chief Business Officer · Since at least Oct 27, 2026 |
| David Sourdive | Executive Vice President CMC & Manufacturing and Director · Since at least May 29, 2026 |
| Jean-Pierre Garnier | Chairman of the Board of Directors - Director · Since at least May 29, 2026 |
| Kyung Nam-Wortman | Executive Vice President, Chief Human Resources Officer · Since at least Nov 5, 2026 |
| Marie-Bleuenn Terrier | General Counsel · Since at least Nov 5, 2026 |
| Patricia Sosa Navarro | Chief of Staff to the CEO · Since at least Oct 27, 2026 |
| Philippe Duchateau | Chief Scientific Officer · Since at least Nov 5, 2026 |
| Stephan Reynier | Chief Regulatory and Pharmaceutical Compliance Officer · Since at least Nov 5, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Steve Doares | Senior Vice President, US Manufacturing and Site Head · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Cellectis S.A.